ArticleBlood cancer journal2024

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.

Ioannis V Kostopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.